Page 80 - EASL POSTGRADUATE COURSE
P. 80
Figure 1. Summary of molecular pathogenesis of NAFLD/NASH HCC.
References (*required reading)
[1] European Association for the Study of the Liver, European Organisation for Research and
Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2012;56:908-943.
[2] Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression
data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-1512
e1502.
[3] Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-ancestry
mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014:1-10.
[4] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol
Hepatol 2013;10:656-665. *
[5] Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells
causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-132.
[6] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal
microbiota and TLR4. Cancer Cell 2012;21:504-516.
[7] Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in
carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12:181-95.
[8] Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D’Orazio A, et al. Prevention
of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific
farnesoid X receptor reactivation. Hepatology 2015;61:161-70.
[9] Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to
nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-107.
[10] Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation
as determinants of liver cancer progression and prognosis. J Hepatol 2013;59:830-841.
80 Postgraduate Course Syllabus • Metabolic Liver Disease
References (*required reading)
[1] European Association for the Study of the Liver, European Organisation for Research and
Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2012;56:908-943.
[2] Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression
data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-1512
e1502.
[3] Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-ancestry
mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014:1-10.
[4] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol
Hepatol 2013;10:656-665. *
[5] Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells
causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-132.
[6] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal
microbiota and TLR4. Cancer Cell 2012;21:504-516.
[7] Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in
carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12:181-95.
[8] Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D’Orazio A, et al. Prevention
of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific
farnesoid X receptor reactivation. Hepatology 2015;61:161-70.
[9] Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to
nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-107.
[10] Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation
as determinants of liver cancer progression and prognosis. J Hepatol 2013;59:830-841.
80 Postgraduate Course Syllabus • Metabolic Liver Disease
